LITERATURE REVIEW

Heart Failure with Preserved Ejection Fraction: A Review of the ACC/AHA Guidelines and Evidence-Based Management Strategy

Vikas Sunder, MD

INTRODUCTION
Heart failure with preserved ejection fraction (HFrEF) is different in that it is driven by a loss of cardiomyocytes and is characterized by ventricular dilation.\(^2\) The presence of ventricular dilation is a key factor distinguishing HFrEF from HFrpEF.\(^2\)

PHARMACOLOGIC MANAGEMENT
There have been numerous advances in the pharmacologic management of HFrEF in the past 25 years related to blockade of the renin-angiotensin-aldosterone system, beta blockade, neprilysin inhibition, and even ventricular assist devices.\(^2\) Unfortunately, most clinical trial data suggests that these modalities do not alter the course of HFrpEF or provide a reduction in mortality. The 2013 ACC/AHA guideline for the management of heart failure gives a class I recommendation that systolic and diastolic blood pressure be controlled in patients with HFrpEF.\(^1\) While control of hypertension is therefore considered a mainstay in management of HFrpEF, there is currently no evidence that reducing the systemic blood pressure improves signs or symptoms of HFrpEF. ACE inhibitors, ARBs, along with beta-blockers, may be used to treat hypertension in patients with HFrpEF as a class IIa recommendation in the ACC/AHA guideline. Data from the ALLHAT trial showed that chlorthalidone could reduce the incidence of new-onset HFrpEF compared with amlodipine and lisinopril, but this pertains to HFrpEF prevention rather than treatment.\(^8\) There is no evidence in clinical studies that ACE inhibitors or ARBs improve morbidity or mortality in patients with HFrpEF. The data is mixed with beta-blockers, with one recent metanalysis showing no cardiovascular or all-cause mortality benefit in patients with HFrpEF.\(^9\) Regarding aldosterone antagonists, data from the TOPCAT trial showed that patients treated with spironolactone had fewer hospitalizations for heart failure as compared to patients treated with placebo, but that spironolactone did not reduce total deaths or hospitalizations from any cause during the study.\(^10\) The ACC/AHA gives a class IIb recommendation for the use of aldosterone antagonists like spironolactone to decrease hospitalizations in HFrpEF.\(^1\) Statins have been shown to be beneficial in some studies. One Swedish study found that patients with HFrpEF had a one-year survival of 85% when they were...
treated with statins versus 80% when not treated with statins. More recently, given that impairment in nitric oxide signaling has been implicated in the pathophysiology of HfPEF, as introduced above, investigators in the INDIE-HfPEF trial tested the use of inhaled inorganic nitrite delivered via a micro-nebulizer versus placebo over a 4-week period. The patients who received the inhaled inorganic nitrate did not demonstrate a statistically significant improved exercise capacity.

**SYMPTOM-BASED MANAGEMENT AND QUALITY OF LIFE**

The only intervention which has consistently been shown to improve quality of life in patients with HfPEF as assessed by the Minnesota Living with Heart Failure Questionnaire is exercise. Referring patients to a cardiac rehabilitation program can improve exercise capacity. Weight loss can also be beneficial in obese patients as caloric restriction has already been shown to improve exercise capacity in patients with HfPEF. Maintenance of fluid balance is a pivotal part of symptom based management of HfPEF. The 2013 ACC/AHA guideline for the management of heart failure gives a class I recommendation that diuretics should be used for relief of volume overload in patients with HfPEF. This recommendation is based off findings from the CHAMPION trial in which patients had pulmonary artery monitors implanted to monitor their hemodynamics and providers made medication adjustments based on this primary data. A number of changes were made to diuretic medications and these patients had a reduction in heart failure related admissions at 6 months.

**MANAGEMENT OF ATRIAL FIBRILLATION**

Atrial fibrillation is very common in patients with HfPEF, and occurs in approximately two-thirds of patients according to a community-based study in Olmstead County, Minnesota. Supraventricular arrhythmias like atrial fibrillation and associated tachycardia are dangerous for patients with HfPEF in that they impair atrial contraction and diastolic filling time. Patients with HfPEF and atrial fibrillation have an increased mortality. The 2013 ACC/AHA guideline recommends management of atrial fibrillation according to published clinical practice guidelines in patients with HfPEF which includes either a rate control or rhythm control strategy.

**MANAGEMENT OF CORONARY ARTERY DISEASE**

Approximately two-thirds of patients with HfPEF have coronary artery disease demonstrated by coronary angiography. Patients with HfPEF and coronary artery disease have a higher mortality. Revascularization of all coronary stenoses greater than 50%, that is, complete revascularization, may be associated with improved outcomes in these patients. One study found that patients with HfPEF and coronary disease who underwent complete revascularization had less reduction in ejection fraction at four-year follow-up echocardiography. Furthermore, patients who underwent complete re-vascularization by percutaneous intervention or bypass grafting survived longer than those patients who underwent incomplete revascularization or had no revascularization performed. Further prospective research is needed to determine optimal management of coronary artery disease in HfPEF. Patients with HfPEF who have angina can be treated symptomatically with beta-blockers or calcium channel blockers.

**CONCLUSION**

Optimal management of HfPEF remains unclear even as its prevalence and economic burden continue to increase. Further prospective trials enrolling this population of patients are needed. Patients with HfPEF represent a heterogenous group and there may not be a “one-size fits all” type of treatment, and this is likely not the best strategy. The latest ACC/AHA guideline for management of heart failure published in 2013 recommends symptomatic management with diuretics and control of co-morbid disease, including hypertension and atrial fibrillation. The evidence clearly supports the use of exercise in patients with HfPEF to both improve quality of life and increase exercise capacity. Further study is needed regarding the optimal amount and form of exercise which could be beneficial. Spironolactone may be used in patients with HfPEF to reduce hospitalizations related to heart failure.

**KEY POINTS**

1. The latest ACC/AHA guideline for management of heart failure provides a class I recommendation that the systolic and diastolic blood pressure be controlled in HfPEF and that diuretics be used for relief of volume overload.
2. Exercise is the only intervention which has been shown to improve quality of life in patients with HfPEF. Patients with HfPEF should be referred to a cardiac rehabilitation program.
3. Aldosterone antagonists may be considered to reduce future hospitalizations related to heart failure based on current evidence.
REFERENCES


